Application of tyrosine kinase inhibitor in preparation of gene edited NK cell culture product
By co-culturing NK cells with a combination of tyrosine kinase inhibitors and cytokines, the problems of overactivation and reduced activity after cryopreservation caused by NKG2A knockout were solved, and the killing function of NK cells was improved, making it suitable for cancer immunotherapy.
Patent Information
- Application Number
- CN202411446999.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-26
AI Technical Summary
Existing technologies are insufficient to effectively address the problems of NK cell overactivation and reduced killing activity after cryopreservation caused by NKG2A knockout, thus affecting the application of NK cells in tumor treatment.
NK cells were co-cultured using a combination of tyrosine kinase inhibitors such as dasatinib and cytokines IL-2, IL-15, NEAA, serum-free culture medium supplements ITS and L-glutamine to enhance their activity and cytotoxic function after cryopreservation.
It significantly improved the cytotoxic activity of NK cells after cryopreservation, enhanced the functional performance of NK cells after cryopreservation, and provided new ideas for the cryopreservation and application of NK cells, especially playing an important role in cancer immunotherapy.
Smart Images

Figure BDA0005087988940000071 
Figure BDA0005087988940000081 
Figure BDA0005087988940000082
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to the use of tyrosine kinase inhibitors in the preparation of gene-edited NK cell culture products. Background Art
[0002] Natural Killer cells (NK cells), as an important part of the innate immune system, play a key role in identifying and eliminating virus-infected cells and tumor cells. NK cells do not rely on pre-existing immune memory, but instead respond rapidly to infection or tumor occurrence by directly identifying and killing abnormal cells. However, there are some inherent limitations in the traditional NK cell therapy for tumors. There are a variety of inhibitory molecules in the tumor microenvironment, such as TGF-β, IL-10, etc., which can inhibit the activation and cytotoxicity of NK cells; inhibitory receptors on the surface of NK cells (such as NKG2A, TIGIT, PD-1, KIRs, etc.) can recognize molecules on the surface of tumor cells, transmit inhibitory signals, and limit the function of NK cells; the proliferation capacity of NK cells is limited, especially in the tumor microenvironment, which limits their number and function; tumor cells can develop a variety of mechanisms to evade NK cell recognition, such as downregulating the expression of MHC class I molecules or upregulating the expression of HLA-E; these limitations limit its effectiveness in clinical applications.
[0003] In order to further improve the anti-tumor activity of NK cells, researchers have begun to explore ways to enhance cytotoxicity by knocking out multiple target genes through gene editing technology. Knocking out inhibitory receptors, such as NKG2A and TIGIT, can reduce inhibitory signals and enable NK cells to more effectively produce and release perforin and granzymes, thereby enhancing the ability to directly kill target cells. Knocking out the inhibitory molecules PD-1 and TIM-3 that are highly expressed in the tumor microenvironment can relieve the inhibition on NK cell function; knocking out genes that promote apoptosis, such as members of the BCL2 family, can increase the survival rate of NK cells; knocking out non-self-recognition molecules, such as HLA-E-bound NKG2A, can enhance NK cell recognition of tumor cells; knocking out molecules that inhibit cytokine production, such as SOCS1 (Suppressor of Cytokine Signaling 1), can increase the secretion of cytokines such as IFN-γ, thereby enhancing the immune response; knocking out receptors or ligands, such as knocking out the TGF-β receptor (TGFBR2), can avoid the immunosuppressive effects mediated by TGF-β in the tumor microenvironment.
[0004] Multi-target modification of NK cells can significantly improve their functions and enhance their potential for application in immunotherapy. However, this process also faces some challenges, including off-target effects, immunogenicity issues, and potential risks of dysfunction. The functions of NK cells are regulated by multiple signaling pathways, among which NKG2A is an important inhibitory receptor, which can not only inhibit the immediate effector function of NK cells, but also maintain the expansion capacity of human NK cells by regulating the proliferation activity of cells and avoiding cell death caused by over-activation. Although the killing ability of natural killer cells is significantly enhanced after knocking out NKG2A, the insufficient number of NK cells is a huge challenge for the clinical application of general off-the-shelf drugs. At present, there is no effective way to solve the proliferation defect caused by NKG2A knockout.
[0005] NK cells may face greater challenges in cryopreservation than T cells, especially in terms of survival period, metabolic requirements, cell surface receptor stability and proliferation capacity. How to protect the survival rate of NK cells during cryopreservation and maintain their killing activity against tumor cells is the key to the application of general off-the-shelf NK cell drugs to tumor patients. There are few reports on the existing technology to effectively improve the killing activity of NK cells after cryopreservation and resuscitation. Summary of the invention
[0006] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide an application of a tyrosine kinase inhibitor in the preparation of a gene-edited NK cell culture product, so as to solve the problems of the prior art.
[0007] To achieve the above objectives and other related objectives, the present invention provides the use of a tyrosine kinase inhibitor in the preparation of a gene-edited NK cell culture product.
[0008] Preferably, the NK cell culture product is used to provide NK cell activity; and / or the inhibitory receptor gene of the gene-edited NK cell is selected from one or more of the TIGIT gene, the NKG2A gene or the TGFBR gene; more preferably, the gene-edited NK cell is a NK cell in which the NKG2A gene is knocked out.
[0009] The present invention also provides a composition for improving the activity of NK cells, wherein the composition comprises cytokine IL-2, cytokine IL-15, NEAA (Non-Essential Amino Acids), serum-free culture medium additives, L-glutamine or its derivatives and a tyrosine kinase inhibitor.
[0010] The present invention also provides use of the above composition in preparing a product for improving NK cell activity.
[0011] The present invention also provides a method for culturing NK cells, the method comprising the following steps:
[0012] After NK cells are mixed with antigens, the aforementioned composition is added and co-cultured for 8-20 days to obtain NK cells that can maintain killing activity after freezing.
[0013] As described above, the use of the tyrosine kinase inhibitor of the present invention in the preparation of gene-edited NK cell culture products has the following beneficial effects:
[0014] The composition provided by the present invention can solve the problem of cell apoptosis caused by excessive cell activation due to NKG2A knockout, can significantly improve the killing activity of NK cells after cryopreservation, and improve the functional performance of NK cells after cryopreservation. This composition plays an important role in the field of immunotherapy, especially cancer immunotherapy, and provides a new idea for the cryopreservation and application of NK cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Shown is a graph showing the results of NK cell purity detection in the present invention.
[0016] Figure 2 The graph shows the results of various combinations of additives in the present invention improving NK cell morphology.
[0017] Figure 3 The graph shows the results of the various additive combinations in the present invention protecting the NK cell cryopreservation and resuscitation killing activity.
[0018] Figure 4 The graph shows the results of the additive combination 5 of the present invention protecting the cryopreserved and revived killing activity of NK cells from different donor sources. DETAILED DESCRIPTION
[0019] The present invention provides the use of a tyrosine kinase inhibitor in the preparation of a gene-edited NK cell culture product.
[0020] In some specific embodiments, the NK cell culture product is used to provide NK cell activity, and the increase is an increase in the activity of gene-edited NK cells after administration of tyrosine kinase compared to before administration of tyrosine kinase.
[0021] In some specific embodiments, the inhibitory receptor gene of the gene-edited NK cell is selected from one or more of the TIGIT gene, the NKG2A gene, or the TGFBR gene. Preferably, the gene-edited NK cell is a NK cell in which the NKG2A gene is knocked out.
[0022] In some embodiments, the tyrosine kinase inhibitor can be selected from one or more of imatinib, dasatinib, nilotinib, sorafenib, sunitinib, vandetanib, crizotinib, pazopanib or ibrutinib. Preferably, the tyrosine kinase inhibitor is dasatinib.
[0023] In some specific embodiments, the working concentration of the tyrosine kinase inhibitor in the NK cell culture product is 1-500nmol / mL. Specifically, the working concentration is 1-5nmol / mL, 5-10nmol / mL, 10-20nmol / mL, 20-50nmol / mL, 50-80nmol / mL, 80-100nmol / mL, 100-150nmol / mL, 150-200nmol / mL, 200-250nmol / mL, 250-300nmol / mL, 300-400nmol / mL or 400-500nmol / mL. Preferably, the working concentration is 10-100nmol / mL.
[0024] The present invention provides a composition for improving the activity of NK cells, wherein the composition comprises cytokine IL-2, cytokine IL-15, NEAA (Non-Essential Amino Acids), a serum-free culture medium additive, L-glutamine or its derivatives and a tyrosine kinase inhibitor.
[0025] In some embodiments, the serum-free medium additive comprises one or more of insulin, transferrin or selenium salt. Preferably, the serum-free medium additive is ITS (Insulin-Transferrin-Selenium).
[0026] In some embodiments, the L-glutamine or its derivative is selected from L-alanyl-L-glutamine. Preferably, the L-glutamine or its derivative is GlutaMAX.
[0027] In some specific embodiments, the tyrosine kinase inhibitor can be selected from one or more of imatinib, dasatinib, nilotinib, sorafenib, sunitinib, vandetanib, crizotinib, pazopanib or ibrutinib. Preferably, the tyrosine kinase inhibitor is dasatinib. The above tyrosine kinase inhibitors are key kinase inhibitors of cell proliferation signaling pathways, and can effectively inhibit premature cell aging and apoptosis caused by excessive cell activation.
[0028] In some specific embodiments, the working concentration of NEAA in the composition is: based on the volume of the NK cell culture system, the volume percentage of NEAA in the NK cell culture system is 1%-10%. Specifically, the volume percentage is 1%-3%, 3%-5%, 5%-8%, 8%-10%. Preferably, the volume percentage is 1%-5%.
[0029] In some specific embodiments, when the serum-free medium additive in the composition is ITS, the working concentration of ITS is 10-100ug / mL. Specifically, the working concentration is 10-25ug / mL, 25-45ug / mL, 45-65ug / mL, 65-85ug / mL or 85-100ug / mL. Preferably, the working concentration is 10-45ug / mL.
[0030] In some specific embodiments, when L-glutamine or its derivative in the composition is GlutaMAX, the working concentration of GlutaMAX is 1-10 mmol / mL. Specifically, the working concentration is 1-3 mmol / mL, 3-5 mmol / mL, 5-8 mmol / mL or 8-10 mmol / mL. Preferably, the working concentration is 1-5 mmol / mL.
[0031] In some embodiments, the working concentration of cytokine IL-2 in the composition is 10-2000 IU / mL. Specifically, the working concentration is 10-50 IU / mL, 50-80 IU / mL, 80-100 IU / mL, 100-200 IU / mL, 200-500 IU / mL, 500-800 IU / mL, 800-1000 IU / mL, 1000-1200 IU / mL, 1200-1500 IU / mL, 1500-1800 IU / mL or 1800-2000 IU / mL. Preferably, the working concentration is 100-1000 IU / mL.
[0032] In some embodiments, the working concentration of cytokine IL-15 in the composition is 1-200 ng / mL. Specifically, the working concentration is 1-5 ng / mL, 5-8 ng / mL, 8-10 ng / mL, 10-20 ng / mL, 20-50 ng / mL, 50-80 ng / mL, 80-100 ng / mL, 100-120 ng / mL, 120-150 ng / mL, 150-180 ng / mL or 180-200 ng / mL. Preferably, the working concentration is 10-100 ng / mL.
[0033] In some embodiments, the working concentration of the tyrosine kinase inhibitor in the composition is 1-500nmol / mL. Specifically, the working concentration is 1-5nmol / mL, 5-10nmol / mL, 10-20nmol / mL, 20-50nmol / mL, 50-80nmol / mL, 80-100nmol / mL, 100-150nmol / mL, 150-200nmol / mL, 200-250nmol / mL, 250-300nmol / mL, 300-400nmol / mL or 400-500nmol / mL. Preferably, the working concentration is 10-100nmol / mL.
[0034] In some embodiments, the composition further comprises one or more of linoleic acid, β-mercaptoethanol or nicotinamide (NAM). Preferably, the composition comprises nicotinamide and / or β-mercaptoethanol.
[0035] Further, when the composition contains nicotinamide, the working concentration of nicotinamide is 1-100mmol / mL. Specifically, the working concentration is 1-3mmol / mL, 3-5mmol / mL, 5-7mmol / mL, 7-10mmol / mL, 10-15mmol / mL, 15-20mmol / mL, 20-30mmol / mL, 30-50mmol / mL, 50-70mmol / mL or 70-100mmol / mL. Preferably, the working concentration is 5-10mmol / mL.
[0036] Further, when the composition contains linoleic acid, the working concentration of linoleic acid is 1-100ug / mL. Specifically, the working concentration is 1-10ug / mL, 10-25ug / mL, 25-45ug / mL, 45-65ug / mL, 65-85ug / mL or 85-100ug / mL. Preferably, the working concentration is 10-25ug / mL.
[0037] Further, when the composition contains β-mercaptoethanol, the working concentration of β-mercaptoethanol is 0.1-10mmol / mL. Specifically, the working concentration is 0.1-1mmol / mL, 1-3mmol / mL, 3-5mmol / mL, 5-8mmol / mL or 8-10mmol / mL. Preferably, the working concentration is 0.1-5mmol / mL.
[0038] The present invention also provides use of the above composition in preparing a product for improving NK cell activity.
[0039] In some specific embodiments, the NK cells are gene-edited NK cells.
[0040] Further, the gene-edited NK cells are selected from NK cells in which one or more genes of the TIGIT gene, NKG2A gene or TGFBR2 gene are knocked out or knocked down. Preferably, the gene-edited NK cells are NK cells in which the NKG2A gene is knocked out.
[0041] In some specific embodiments, the NK cells are cryopreserved NK cells.
[0042] The present invention also provides a method for culturing NK cells, the method comprising the following steps:
[0043] After NK cells are mixed with antigens, the aforementioned composition is added and co-cultured for 8-20 days to obtain NK cells that can maintain killing activity after freezing.
[0044] In some embodiments, the antigen is an antigen peptide or an antigen presenting cell. Preferably, the antigen is an antigen presenting cell. More preferably, the antigen presenting cell is EK562.
[0045] In some specific embodiments, based on the volume of the mixed culture system, the number ratio of NK cells to antigens is 1:0.1-1:5. Specifically, the number ratio is 1:0.1-1:0.2, 1:0.2-1:0.5, 1:0.5-1:0.8, 1:0.8-1:1, 1:1-1:1.5, 1:1.5-1:2, 1:2-1:3, 1:3-1:4 or 1:4-1:5. Preferably, the number ratio is 1:0.5-1:2.
[0046] In some embodiments, the co-cultivation period is 8-10, 10-12, 12-14, 14-16, 16-18 or 18-20 days. Preferably, the co-cultivation period is 12-16 days.
[0047] In some specific embodiments, the co-culture condition is an environment with a temperature of 37° C. and a CO 2 concentration of 5%.
[0048] Under normal circumstances, NKG2A binds to HLA-E, transmits inhibitory signals, and helps maintain the homeostasis of NK cells. After NKG2A is knocked out, NK cells cannot receive inhibitory signals, activation signals are enhanced, and NK cell killing activity is improved, but it will cause NK cells to be overactivated. Overactivated NK cells will release more cytokines, such as IFN-γ, TNF-α, etc. These cytokines can further activate NK cells and other immune cells, forming a positive feedback loop. Continuous activation and cytokine release will lead to increased energy consumption and metabolic pressure of NK cells, which may lead to NK cell apoptosis, which is a mechanism of cell self-protection to avoid excessive immune response and tissue damage.
[0049] During the freezing process, the water inside and outside the cells will form ice crystals, which will cause physical damage to the cell membrane; the low temperature environment will slow down the cell's metabolic rate, affect the cell's energy supply, and reduce cell activity; certain receptors on the cell surface (such as NKG2A, NKG2D, etc.) may change during the freezing process. All of the above factors will affect the killing function of NK cells after cryopreservation and resuscitation.
[0050] In the present invention, NEAA is used to maintain the healthy state of cells and provide cells with necessary nutrition and energy; ITS contains ingredients such as insulin, transferrin and selenium, and is used to promote cell growth and proliferation under serum-free culture conditions; GlutaMAX is a stable form of L-glutamine, which is used to provide important amino acids required for cell growth and support cell metabolism and proliferation; linoleic acid is used to maintain the structural integrity of cell membranes and promote the proliferation of NK cells; β-mercaptoethanol (2-Mercaptoethanol) is used to reduce oxidative stress in the culture medium, which is beneficial to the survival and proliferation of NK cells; tyrosine kinase inhibitors are used to reduce immune responses by inhibiting the activation and proliferation of T cells, and can also be used to control the activity of CAR-T cells as part of an on / off control drug to help regulate immune responses and avoid over-activation; cytokines IL-2, cytokines IL-15 and nicotinamide are used to maintain NK cell activity and promote NK cell proliferation.
[0051] The composition provided by the present invention can solve the problem of cell apoptosis caused by excessive cell activation due to NKG2A knockout, can significantly improve the killing activity of NK cells after cryopreservation, and improve the functional performance of NK cells after cryopreservation. This composition plays an important role in the field of immunotherapy, especially cancer immunotherapy, and provides a new idea for the cryopreservation and application of NK cells.
[0052] In the present invention, the meaning of "working concentration" is the concentration at which each component exerts its effect based on the volume of the NK cell culture system.
[0053] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0054] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0055] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0056] The sources of the reagents used in the examples of the present invention are as follows:
[0057] NEAA was purchased from Thermo; ITS was purchased from Thermo; GlutaMAX was purchased from Thermo; Dasatinib was purchased from MCE; cytokine IL-2 was purchased from Jiangsu Jinsili Pharmaceutical; cytokine IL-12 was purchased from Novoprotein; cytokine IL-15 was purchased from Novoprotein; and nicotinamide (NAM) was purchased from Sigma.
[0058] Example 1 Detection of base-edited NK cell functionality
[0059] 1.1 NK cell culture process
[0060] 1.1.1 Take the frozen NK seed cells and frozen irradiated EK562 engineered cells, thaw them quickly in a 37℃ water bath, and transfer the cells into serum-free culture medium after thawing.
[0061] 1.1.2 Centrifuge at 500g for 5 minutes.
[0062] 1.1.3 Discard the supernatant and resuspend the cells in 5 mL of NK cell culture medium.
[0063] 1.1.4 Take samples to test cell density and viability. According to the counting results, the ratio of feeder cells EK562: NK cells is about 2:1. Transfer them into a new culture bottle and add appropriate amount of culture medium. The NK cell culture density is about 1×10 6 cells / mL.
[0064] 1.1.5 Add 5% serum replacement to the culture flask and supplement with 200 IU / mL interleukin-2 according to the total volume.
[0065] 1.1.6 Place in a carbon dioxide incubator (37°C, 5% CO2 concentration) for culture.
[0066] 1.1.7D2-3 days, add pre-warmed serum-free medium and 5% serum replacement in an amount of about 0.2-1 times the original culture volume, and add 200 IU / mL interleukin-2 according to the total volume after rehydration.
[0067] 1.1.8D4-7 days, gently shake the culture bottle, use a 10mL pipette to take about 0.2mL of cell suspension for counting, and avoid blowing when sampling. Add preheated serum-free culture medium and 5% serum replacement according to the counting results, and add 200IU / mL interleukin-2 according to the total volume after rehydration.
[0068] 1.1.9 After culturing for 7-8 days, count the NK cells. At this time, the CD3 - CD56 + The ratio can reach more than 95%, refer to Figure 1 (The horizontal and vertical axes of the rightmost figure are 10 0 , 10 1 , 10 2 , 10 3 , 10 4 , 10 5 and 10 6 ).
[0069] 1.2 Electroporation transfection of NK cells
[0070] 1.2.1 According to Example 1, 7 groups of comparative examples were set up, and the differences between the knockout targets and those in Example 1 are shown in Table 1:
[0071] Table 1 Knockout target design for different comparison ratios in each group
[0072]
[0073]
[0074] 1.2.2 Collect the primary NK cells expanded in vitro in step 1.1.9 of Example 1, count the cells, and collect 8×10 6 NK cells were centrifuged at 500 g for 5 min at room temperature.
[0075] 1.2.3 Discard the supernatant, resuspend the cell pellet in DPBS buffer, wash, and centrifuge at 500g for 5 minutes at room temperature.
[0076] 1.2.4 Discard the supernatant and resuspend the NK cells using the electroporation buffer provided with the Lonza electroporator.
[0077] 1.2.5 Add sgRNA (TIGIT, NKG2A, TGFBR2) and base editing protein and mix well.
[0078] 1.2.6 Use Lonza electroporator for electroporation transfection, and set the electroporation program to CM189. After completion, take out the electroporation cup and let it stand for 5 minutes to facilitate the recovery of the electroporated NK cell membrane.
[0079] 1.2.7 Thaw the frozen irradiated EK562 engineered cells, resuspend them in NK culture medium, and count them.
[0080] 1.2.8 Use an extended pipette to aspirate the cell suspension and place it in preheated culture medium for culture. The feeder cell EK562: NK cell ratio is about 1:1 and transferred to a new culture bottle. After continuing to culture for 14 days, flow cytometry is used to detect the editing efficiency of the three targets TIGIT, NKG2A, and TGFBR2, NK cell purity, and NK cell killing activity.
[0081] 1.3 Detection indicators
[0082] 1.3.1 Flow cytometry detection of target knockout efficiency and NK purity
[0083] 1.3.1.1 Each group takes 1×10 6 The cells were collected into 1.5 mL EP tubes and centrifuged at 500 g for 5 min.
[0084] 1.3.1.2 Remove the supernatant, wash once with washing buffer (PBS containing 2% FBS), remove the supernatant, and add 100ul of washing buffer to resuspend the cells.
[0085] 1.3.1.3 Add 1ul of CD3, CD56, TIGIT, TGFBR2, and NKG2A antibodies to each group and stain for 20 minutes at room temperature in the dark.
[0086] 1.3.1.4 After staining, wash twice with washing buffer, resuspend the cell pellet with 500ul washing buffer and prepare for flow cytometry. The results are shown in Table 2.
[0087] Table 2 Flow cytometry detection of knockout efficiency of each target
[0088]
[0089]
[0090] 1.3.2 Proliferation data statistics
[0091] 1.3.2.1 After electroporation, observe the cell status every day, take samples and count, gently shake the culture bottle, and avoid blowing when taking samples. Add preheated serum-free culture medium and 5% serum replacement according to the counting results, add 200 IU / mL interleukin-2 according to the total volume after rehydration, and adjust the cell density to about (1-3)×10 6 cells / mL.
[0092] 1.3.2.2 According to the counting results, the cell proliferation multiples were calculated 7-14 days and 14-21 days after electroporation. The results are shown in Table 3.
[0093] Table 3 NK cell proliferation times after electroporation
[0094]
[0095] The above data show that the total cell proliferation multiples of the non-NKG2A knockout group were close to that of the wild-type NK cells in comparison example 7. The cell proliferation of the NKG2A knockout group, regardless of the single-target, dual-target, or triple-target group, was significantly reduced, especially in the third week, when the cell state was poor and the viability was low, indicating that NKG2A not only acts as an inhibitory receptor, but also participates in the development and proliferation of NK cells.
[0096] Example 2 Testing cytokines to enhance base editing NK cell proliferation
[0097] 2.1 Provide necessary cytokines during the culture process of base-edited NK cells in order to effectively improve the proliferation ability of NK cells.
[0098] 2.2 Cytokine IL-2 is one of the key factors for NK cell proliferation. It promotes the proliferation and survival of NK cells by activating the JAK-STAT signaling pathway. IL-2 can also enhance the cytotoxic effect of NK cells. In NK cell culture, the concentration of IL-2 is usually 100-1000IU / mL.
[0099] 2.3 Cytokine IL-7 plays an important role in the early development and survival of NK cells. It can work synergistically with IL-2 to further enhance the proliferation of NK cells. IL-7 can also support the maturation and function of NK cells. The concentration of IL-7 in NK cell culture is usually low, about 1-10ng / mL.
[0100] 2.4 Cytokine IL-12 can enhance the activation state of NK cells and promote the production of IFN-γ. Although IL-12 itself does not directly promote the proliferation of NK cells, it can indirectly promote the function of NK cells by increasing the level of IFN-γ. The concentration of IL-12 in NK cell culture is usually 1-10ng / mL.
[0101] 2.5 Cytokine IL-15 is similar to IL-2, but more powerful, and is essential for the proliferation and survival of NK cells. It works by sharing the β and γ subunits of the receptor with IL-2. IL-15 can also enhance the cytotoxic effect of NK cells. The concentration of IL-15 in NK cell culture is usually 10-100ng / mL.
[0102] 2.6 Cytokine IL-18 is a multifunctional cytokine that is widely used in cell culture and can regulate the immune system and inflammatory response. IL-18 can promote cell proliferation and differentiation, and help cell growth and development. In cell culture, the concentration of IL-18 is usually between 10ng / ml and 100ng / ml.
[0103] 2.7IFN-γ (Interferon-gamma) is a cytokine produced by activated NK cells, which can further enhance the function of NK cells. It does not directly promote the proliferation of NK cells, but can indirectly promote the function of NK cells by enhancing the cytotoxic effect of NK cells. The concentration of IFN-γ in NK cell culture is usually 10-100ng / mL.
[0104] 2.8EGTA (Ethylene Glycol Bis(β-Aminoethyl Ether)N,N,N',N'-Tetraacetic Acid) is a chelating agent that can chelate calcium ions, thereby affecting signaling pathways that depend on calcium ions. In some cases, EGTA can be used to inhibit specific signaling pathways, thereby affecting the function of NK cells. The effect of EGTA in NK cell culture is usually not to directly promote cell proliferation, but to affect the function of NK cells by regulating signal transduction pathways. The concentration in cell culture is usually 0.1-10ng / mL.
[0105] 2.9 The above factors are used in combination to optimize the proliferation and function of NK cells. The specific combinations are shown in Table 4.
[0106] Table 4 Combination design table for improving NK cell proliferation
[0107]
[0108]
[0109]
[0110] 2.10 The NK cell proliferation data after electroporation of all the above compositions are summarized, and the results are shown in Table 5.
[0111] Table 5 Results of various factor combinations to improve NK cell proliferation
[0112]
[0113]
[0114] Among the above-mentioned cytokine compositions, IFN-γ, IL-7, IL-18, and EGTA had almost no improvement on NK cell proliferation. The combination of IL-2, IL-12, and IL-15 improved NK cell proliferation 7 to 14 days after electroporation to a certain extent, but the data from 14 to 21 days showed that proliferation was not significantly improved.
[0115] Example 3 Testing various additives to improve base editing NK cell proliferation
[0116] 3.1 Provide necessary nutrients, antioxidant protection and regulate cell activation levels during NK cell culture in order to effectively improve the proliferation capacity of NK cells.
[0117] 3.2NEAA is a non-essential amino acid, which is essential for maintaining the health of cells and promoting cell proliferation, especially when these amino acids are lacking in the culture medium.
[0118] 3.3ITS (Insulin-Transferrin-Selenium) is a nutritional supplement containing ingredients such as insulin, transferrin and selenium, which can promote cell growth and proliferation, especially under serum-free culture conditions.
[0119] 3.4GlutaMAX is a stable form of L-glutamine that can provide important amino acids required for cell growth and support cell metabolism and proliferation.
[0120] 3.5 Linoleic Acid is an essential fatty acid that is essential for the structural integrity of cell membranes and can promote the proliferation of NK cells.
[0121] 3.6β-Mercaptoethanol is an antioxidant that can reduce oxidative stress in the culture medium and is beneficial to the survival and proliferation of NK cells.
[0122] 3.7 Dasatinib is a tyrosine kinase inhibitor that works by inhibiting the activity of multiple tyrosine kinases (including Bcr-Abl, Src family kinases, etc.). It can block abnormal signal transduction pathways, thereby slowing or stopping the growth and spread of leukemia cells. It is suitable for adult patients with all stages of chronic myeloid leukemia (CML) (chronic phase, accelerated phase, lymphocytic blast phase, and myeloid blast phase) who are resistant or intolerant to treatment regimens including imatinib mesylate, as well as adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who are resistant or intolerant to previous treatment drugs. Dasatinib can reduce immune responses by inhibiting the activation and proliferation of T cells, and can also be used to control the activity of CAR-T cells as part of an on / off control drug to help regulate immune responses and avoid over-activation.
[0123] 3.8 Nicotinamide (NAM) is a form of vitamin B3. It can participate in a variety of biochemical reactions in the body and is one of the important precursors for the synthesis of nicotinamide adenine dinucleotide (NAD+). It participates in the synthesis of NAD+. Nicotinamide can participate in the synthesis of NAD+ through the salvage synthesis pathway. In this process, nicotinamide is first converted into nicotinamide mononucleotide (NMN) by nicotinamide phosphoribosyltransferase (NAMPT), and then NMN is converted into NAD+ by nicotinamide mononucleotide adenosyltransferase (NMNAT). NAD+ plays an important role in cells. It is a coenzyme for many redox reactions and is involved in the regulation of many aspects such as DNA repair, cell aging and energy metabolism.
[0124] 3.9 The above-mentioned additives are used in combination to optimize the proliferation and function of NK cells. The specific combinations are shown in Table 6.
[0125] Table 6 Design of additive combinations for improving NK cell proliferation
[0126]
[0127] 3.10 The NK cell proliferation data after electroporation of all the above compositions are summarized, and the results are shown in Table 7.
[0128] Table 7 Results of various additive combinations to improve NK cell proliferation
[0129]
[0130]
[0131] Among the above-mentioned culture medium additive compositions, combination 3 (NEAA combined with ITS combined with GlutaMAX combined with IL-2 combined with IL-15 combined with Dasatinib), combination 5 (NEAA combined with ITS combined with GlutaMAX combined with Dasatinib combined with IL-2 combined with IL-15 combined with NAM), combination 8 (NEAA combined with ITS combined with GlutaMAX combined with β-mercaptoethanol combined with IL-2 combined with IL-15 combined with Dasatinib combined with NAM), combination 11 (NEAA combined with ITS combined with GlutaMAX combined with β-mercaptoethanol combined with IL-2 combined with IL-15 combined with Dasatinib) significantly enhances NK cell proliferation, solves the problem of cell apoptosis caused by excessive cell activation caused by NKG2A knockout, and can achieve large-scale NK cell expansion. Since cell membrane damage, reduced metabolic activity, and impaired cell surface receptor function may occur during the freezing process, resulting in reduced killing activity, if the above-mentioned optimized NK cells can be cryopreserved, they can form a universal off-the-shelf product so that they can be provided to tumor patients in need of treatment at any time. This ready-to-use NK cell drug can be quickly applied to a wide range of patient groups without waiting for an individualized preparation process, greatly improving the accessibility and convenience of treatment.
[0132] 3.11 Summary of NK cell morphological changes
[0133] Base-edited NK cells may have cell morphology changes due to over-activation, and the cells are thin and weak. Among the culture medium additive combinations, combination 3, combination 5, combination 8, and combination 11 not only promoted cell proliferation compared with the negative control combination 14, but also improved the cell morphology, making it fuller. The results are shown in Figure 2 .
[0134] Example 4 Testing and screening of compositions to improve the freezing killing activity of base-edited NK cells
[0135] 4.1 Collect NK cells from combination 3, combination 5, combination 8, combination 11, combination 14, and WT cultured for 21 days for cryopreservation, 5×10 6 After 48 hours, cells in each group were revived, resuspended in NK medium, and placed in a carbon dioxide incubator. H929 tumor cells were counted and added to a 96-well plate at 20,000 cells / well, with a final volume of 50 μL.
[0136] 4.2 Place the 96-well plate in a carbon dioxide incubator and culture the tumor cells for 2-3 hours to allow them to adhere to the wall.
[0137] 4.3 After counting, 50 μL of NK cells were added to the 96-well plate at a ratio of NK cells to tumor cells of 1:1 for combination 3, combination 5, combination 8, and combination 11.
[0138] 4.4 Make three replicate wells for each group, and set up three control wells for tumor cell culture alone.
[0139] 4.5 Place the 96-well cell culture plate on a real-time dynamic detector (IncuCyte S3, Sartorius) and take photos for 24 hours.
[0140] 4.6 After 24 hours, the fluorescence intensity of the cells was detected by real-time dynamic detector.
[0141] 4.7 Calculate the NK cell killing rate, the result is as follows Figure 3 , as shown in Table 8:
[0142] Table 8 Statistical analysis results of each group of data
[0143]
[0144] Compared with WT and control group combination 14, combination 3, combination 5, combination 8, and combination 11 all improved the cell killing activity after cryopreservation and resuscitation (P < 0.05), among which combination 5 was superior to other groups, indicating that the combined use of NEAA, ITS, GlutaMAX, Dasatinib, IL-2, IL-15, and NAM not only increased the proliferation multiples of base-edited NK cells, but also avoided the phenomenon of reduced killing activity during cell cryopreservation.
[0145] Example 5 Testing and screening of composition 5 to improve the stability of NK cell cryopreservation and resuscitation killing activity
[0146] 5.1 Recovery of NK cells from donors 1, 2, and 3
[0147] 5.2 The seed cell culture process is the same as in Example 1. After electroporation, base-edited NK cells are cultured using composition 5 and then enter expansion culture. A control group and an experimental group are designed.
[0148] 5.3 Donor1, Donor2, and Donor3 were collected and cryopreserved for 21 days. 5×10 6 After 48 hours, cells in each group were revived, resuspended in NK culture medium, and placed in a carbon dioxide incubator.
[0149] 5.4 Count the H929 tumor cells and add 20,000 tumor cells / well to a 96-well plate in a final volume of 50 μL.
[0150] 5.5 Place the 96-well plate in a carbon dioxide incubator and culture the tumor cells for 2-3 hours to allow them to adhere to the wall.
[0151] 5.6 After counting Donor1, Donor2, and Donor3, 50 μL of NK cells were added to the 96-well plate at a ratio of NK cells to tumor cells of 1:1.
[0152] 5.7 Make three replicate wells for each group, and set up three control wells for tumor cell culture alone.
[0153] 5.8 Place the 96-well cell culture plate on a real-time dynamic detector (IncuCyte S3, Sartorius) and take photos for 24 hours.
[0154] 5.9 After 24 hours, the fluorescence intensity of the cells was detected by real-time dynamic detector.
[0155] 5.10 Calculate the NK cell killing rate. The result is as follows Figure 4 , as shown in Table 9:
[0156] Table 9 Statistical analysis results of each group of data
[0157]
[0158] Figure 4 The data in Table 9 showed that the cytotoxic activity of Donor1, Donor2 and Donor3 groups after cryopreservation and resuscitation was significantly improved (P < 0.05), indicating that the combined use of NEAA, ITS, GlutaMAX, Dasatinib, IL-2, IL-15 and NAM can improve the cytotoxic activity of NK cells from donors of different sources after cryopreservation and resuscitation. The combined use of these components can work synergistically to provide NK cells with necessary growth factors and trace elements, maintain the stability of the intracellular environment, and enhance the function of NK cells, especially maintaining a high cytotoxic activity after cryopreservation and resuscitation, which has very important clinical application value for NK cell therapy.
[0159] In summary, the present invention discovered for the first time that the combined use of a composition (NEAA, ITS, GlutaMAX, Dasatinib, IL-2, IL-15, NAM) can solve the problem of cell apoptosis caused by excessive cell activation due to NKG2A knockout, and the killing functionality of NK cell cryopreservation and resuscitation is improved.
[0160] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.
Claims
1. Application of tyrosine kinase inhibitors in the preparation of gene-edited NK cell culture products.
2. The use according to claim 1, characterized in that: The NK cell culture product is used to provide NK cell activity; and / or, the inhibitory receptor gene of the gene-edited NK cell is selected from one or more genes of the TIGIT gene, the NKG2A gene or the TGFBR gene; preferably, the gene-edited NK cell is a NK cell in which the NKG2A gene is knocked out.
3. The use according to claim 1, characterized in that: The tyrosine kinase inhibitor is selected from one or more of imatinib, dasatinib, nilotinib, sorafenib, sunitinib, vandetanib, crizotinib, pazopanib or ibrutinib; preferably, the tyrosine kinase inhibitor is dasatinib.
4. The use according to claim 1, characterized in that: The working concentration of the tyrosine kinase inhibitor in the NK cell culture product is 1-500nmol / mL.
5. A composition for improving NK cell activity, characterized in that: The composition comprises cytokine IL-2, cytokine IL-15, NEAA, serum-free medium supplement, L-glutamine or its derivatives and a tyrosine kinase inhibitor.
6. The composition according to claim 5, characterized in that The composition comprises one or more of the following features: a1) the serum-free medium additive comprises one or more of insulin, transferrin or selenium salt; preferably, the serum-free medium additive is ITS; a2) the L-glutamine or its derivative is selected from L-alanyl-L-glutamine; preferably, the L-glutamine or its derivative is GlutaMAX; a3) The tyrosine kinase inhibitor is selected from one or more of imatinib, dasatinib, nilotinib, sorafenib, sunitinib, vandetanib, crizotinib, pazopanib or ibrutinib; preferably, the tyrosine kinase inhibitor is dasatinib.
7. The composition according to claim 5, characterized in that The composition comprises one or more of the following features: b1) the working concentration of NEAA in the composition is: based on the volume of the NK cell culture system, the volume percentage of NEAA in the NK cell culture system is 1%-10%; b2) when the serum-free medium additive in the composition is ITS, the working concentration of ITS is 10-100 ug / mL; b3) when L-glutamine or its derivative in the composition is GlutaMAX, the working concentration of GlutaMAX is 1-10 mmol / mL; b4) the working concentration of cytokine IL-2 in the composition is 10-2000 IU / mL; b5) the working concentration of cytokine IL-15 in the composition is 1-200 ng / mL; b6) The working concentration of the tyrosine kinase inhibitor in the composition is 1-500 nmol / mL.
8. The composition according to claim 5, characterized in that The composition further comprises one or more of linoleic acid, β-mercaptoethanol or niacinamide; preferably, the composition comprises niacinamide and / or β-mercaptoethanol.
9. The composition according to claim 8, characterized in that When the composition contains nicotinamide, the working concentration of nicotinamide is 1-100 mmol / mL; and / or, when the composition contains β-mercaptoethanol, the working concentration of β-mercaptoethanol is 0.1-10 mmol / mL; and / or, when the composition contains linoleic acid, the working concentration of linoleic acid is 1-100 ug / mL.
10. Use of the composition according to any one of claims 5 to 9 in the preparation of a product for improving NK cell activity.
11. The use according to claim 10, characterized in that The NK cells are gene-edited NK cells.
12. The use according to claim 11, characterized in that The gene-edited NK cells are selected from NK cells in which one or more genes among TIGIT gene, NKG2A gene or TGFBR gene are knocked out or knocked down; preferably, the gene-edited NK cells are NK cells in which NKG2A gene is knocked out.
13. The use according to claim 11, characterized in that The NK cells are frozen NK cells.
14. A method for culturing NK cells, characterized in that: The culture method comprises the following steps: After NK cells are mixed with antigens, the composition described in any one of claims 5 to 9 is added and co-cultured for 8 to 20 days to obtain NK cells that can maintain killing activity after freezing.
15. The culture method according to claim 14, characterized in that: The culture method comprises one or more of the following features: c1) the antigen is an antigen peptide or an antigen presenting cell; preferably, the antigen is an antigen presenting cell; more preferably, the antigen presenting cell is EK562; c2) based on the volume of the mixed culture system, the ratio of NK cells to antigens is 1:0.1-1:5; c3) the co-cultivation period is 12-16 days; c4) The co-culture conditions are an environment with a temperature of 37° C. and a CO 2 concentration of 5%.
